Research ExplorerPublicationsOne-year clinical outcomes of a novel transcatheter heart va...

One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study

Standard

One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study. / Schäfer, Ulrich; Butter, Christian; Landt, Martin; Frerker, Christian; Treede, Hendrik; Schirmer, Johannes; Koban, Cornel; Allali, Abdelhakim; Schmidt, Tobias; Charitos, Efstratios; Nikolayevska, Olga; Conradi, Lenard.

In: EUROINTERVENTION, Vol. 17, No. 13, 28.01.2022, p. 1077-1080.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schäfer, U, Butter, C, Landt, M, Frerker, C, Treede, H, Schirmer, J, Koban, C, Allali, A, Schmidt, T, Charitos, E, Nikolayevska, O & Conradi, L 2022, 'One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study', EUROINTERVENTION, vol. 17, no. 13, pp. 1077-1080. https://doi.org/10.4244/EIJ-D-20-01241

APA

Schäfer, U., Butter, C., Landt, M., Frerker, C., Treede, H., Schirmer, J., Koban, C., Allali, A., Schmidt, T., Charitos, E., Nikolayevska, O., & Conradi, L. (2022). One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study. EUROINTERVENTION, 17(13), 1077-1080. https://doi.org/10.4244/EIJ-D-20-01241

Vancouver

Schäfer U, Butter C, Landt M, Frerker C, Treede H, Schirmer J et al. One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study. EUROINTERVENTION. 2022 Jan 28;17(13):1077-1080. https://doi.org/10.4244/EIJ-D-20-01241

Bibtex

@article{f73f3f81e2e24496839918ac679ca2d4,
title = "One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study",
abstract = "First-in-human clinical studies and in vitro tests for valve-in-valve (ViV) with the ALLEGRA (New Valve Technology) transcatheter heart valve (THV), as well as the 30-day data of the VIVALL study demonstrated favourable results, even in small surgical aortic bioprostheses123. This paper reports the 12-month outcomes of the VIVALL study.",
keywords = "Aortic Valve/diagnostic imaging, Bioprosthesis, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation/adverse effects, Heart Valves, Humans, Prosthesis Design, Prosthesis Failure, Surgical Instruments, Transcatheter Aortic Valve Replacement/adverse effects, Treatment Outcome",
author = "Ulrich Sch{\"a}fer and Christian Butter and Martin Landt and Christian Frerker and Hendrik Treede and Johannes Schirmer and Cornel Koban and Abdelhakim Allali and Tobias Schmidt and Efstratios Charitos and Olga Nikolayevska and Lenard Conradi",
year = "2022",
month = jan,
day = "28",
doi = "10.4244/EIJ-D-20-01241",
language = "English",
volume = "17",
pages = "1077--1080",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "13",

}

RIS

TY - JOUR

T1 - One-year clinical outcomes of a novel transcatheter heart valve to treat degenerated surgical valves: the VIVALL study

AU - Schäfer, Ulrich

AU - Butter, Christian

AU - Landt, Martin

AU - Frerker, Christian

AU - Treede, Hendrik

AU - Schirmer, Johannes

AU - Koban, Cornel

AU - Allali, Abdelhakim

AU - Schmidt, Tobias

AU - Charitos, Efstratios

AU - Nikolayevska, Olga

AU - Conradi, Lenard

PY - 2022/1/28

Y1 - 2022/1/28

N2 - First-in-human clinical studies and in vitro tests for valve-in-valve (ViV) with the ALLEGRA (New Valve Technology) transcatheter heart valve (THV), as well as the 30-day data of the VIVALL study demonstrated favourable results, even in small surgical aortic bioprostheses123. This paper reports the 12-month outcomes of the VIVALL study.

AB - First-in-human clinical studies and in vitro tests for valve-in-valve (ViV) with the ALLEGRA (New Valve Technology) transcatheter heart valve (THV), as well as the 30-day data of the VIVALL study demonstrated favourable results, even in small surgical aortic bioprostheses123. This paper reports the 12-month outcomes of the VIVALL study.

KW - Aortic Valve/diagnostic imaging

KW - Bioprosthesis

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Heart Valves

KW - Humans

KW - Prosthesis Design

KW - Prosthesis Failure

KW - Surgical Instruments

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Treatment Outcome

U2 - 10.4244/EIJ-D-20-01241

DO - 10.4244/EIJ-D-20-01241

M3 - SCORING: Journal article

C2 - 33775931

VL - 17

SP - 1077

EP - 1080

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 13

ER -